2SEVENTY BIO INC (TSVT)

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

Bullish Two Hundred Day Moving Average Cross - TSVT

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are the perfect way to start the week as we dive into the biggest stories moving shares on Monday!

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

Commit To Purchase 2seventy bio At $2.50, Earn 182.5% Annualized Using Options

TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023

TSVT stock results show that 2seventy bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips 2seventy bio (NASDAQ:TSVT) just reported results for the fourth quarter of 2023...

2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress

2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...

2seventy bio (TSVT) Shares Cross Above 200 DMA

2seventy bio to Participate in Upcoming Investor Conferences

Bristol Myers to face FDA panel for Abecma label expansion

The U.S. FDA will hold an AdCom meeting in March to dicuss a label expansion for Abecma developed by Bristol Myers Squibb (BMY) and 2seventy bio (TSVT). Read more here.

Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Bristol-Myers Squibb Q4 beats driven by Eliquis and Opdivo

Bristol-Myers Squibb's (BMY) Q4 2023 results exceeded estimates, driven by strong sales of Eliquis and Opdivo, amid underperforming Revlimid. Read more here.

Leerink ups 2seventy to outperform, cites attractiveness as takeover target (NASDAQ:TSVT)

Leerink has upgraded 2seventy bio (TSVT) to outperform, citing the company’s attractiveness as an acquisition target. “While a commercial company with flat reve

2seventy stock rises as Regeneron acquires R&D assets (NASDAQ:REGN)

Regeneron Pharmaceuticals announces the formation of Regeneron Cell Medicines, acquiring assets from 2seventy bio to advance cell therapies in oncology and...

2seventy bio Announces New Strategic Path Forward

Bristol-Myers Squibb Abecma set for expanded EU nod (NYSE:BMY)

Bristol Myers Squibb (BMY) wins positive opinion in the EU for expanded approval for Abecma, a multiple myeloma drug it markets with 2seventy bio (TSVT). Read more here.

Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3

2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)